

- **Principle** – record the Committee meeting attendance, running, discussions
- **Links to include** – none
- **Attachments to include** – none
- **Info to include** – guideline title; meeting date/location; status of minutes (draft/confirmed); attendees; observers; apologies; agenda items and related discussions; declarations of interest; date of next meeting

Osteoporosis: risk assessment, treatment and prevention of fragility fractures Committee meeting 14

Date: 28/01/2025

Location: Virtual (Zoom)

Minutes: Final

Committee members present:

Maragret Lally (Chair)	(Present for notes 1 – 7)
Nicola Peel (Topic adviser)	(Present for notes 1 – 7)
Alison Ahmed	(Present for notes 1 – 7)
Irene Baker	(Present for notes 1 – 7)
Sherwin Criseno	(Present for notes 1 – 7)
Elaine Dennison	(Present for notes 1 – 7)
Paul Hamilton	(Present for notes 1 – 7)
Karen Knapp	(Present for notes 1 – 7)
Kay Morgan	(Present for notes 1 – 7)
Rachel Muir	(Present for notes 1 – 7)
Nicholas Pipkin	(Present for notes 1 – 7)
Stuart Ralston	(Present for notes 1 – 7)
Rajesh Varma	(Present for notes 1 – 7)
Karen Whitehead	(Present for notes 1 – 7)

In attendance:

Rebecca Boucher	Content Designer	(Present for notes 1 – 7)
Annette Chalker	Technical Analyst	(Present for notes 1 – 7)
Linyun Fun	Technical Analyst	(Present for notes 1 – 7)
Amber Hernaman	Project Manager	(Present for notes 1 – 7)
Clare Jones	Senior Technical Analyst	(Present for notes 1 – 7)

4.0.03 DOC Cmte minutes

Qudsia Malik	Senior Technical Analyst	(Present for notes 1 – 7)
Lisa Miles	Technical Analyst	(Present for notes 1 – 7)
Suzie Panek	Resource Impact	(Present for notes 1 – 7)
Muksitur Rahman	Health Economist	(Present for notes 1 – 7)
Carlos Sharpin	Guideline Lead	(Present for notes 1 – 7)

Apologies:

Iain Macleod	Committee member
Sarah Glover	Information specialist
Daniel Smithson	Technical analyst

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 14th Osteoporosis guideline committee.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included.

- Electronic health records evidence review
- Revisiting recommendations on follow up/monitoring for people on treatment
- Revisiting recommendations on risk assessment tools
- Electronic plan update

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was on follow up/monitoring for people on treatment and risk assessment tools.

The Chair asked everyone to verbally declare any interests that had arisen since the last meeting.

Name	Affiliation	Declarations of Interest, date declared	Type of interest	Decision taken
Stuart Ralston	Committee member	Chairman of the Paget's Association	Direct, non-financial professional and personal	Declare and participate.

4.0.03 DOC Cmte minutes

			interests	
Stuart Ralston	Committee member	Former Chair SIGN guidance on osteoporosis	Direct, non-financial professional and personal interests	Declare and participate.
Stuart Ralston	Committee member	Member of the Board of Trustees of the Charity Pregnancy-Associated Osteoporosis UK	Direct, non-financial professional and personal interests	Declare and participate.
Stuart Ralston	Committee member	Lectures on my clinical experience in the management of osteoporosis (Funding to my employer from UCB pharmaceuticals)	Indirect interest	Declare and participate.
Stuart Ralston	Committee member	Supply of Teriparatide free of charge for a clinical trial in osteogenesis imperfecta (Eli Lilly)	Indirect interest	Declare and participate.
Stuart Ralston	Committee member	Co-applicant on a grant application to UCB to evaluate clinical outcomes of anabolic therapy in the treatment of osteoporosis	Indirect interest	Declare and participate.
Stuart Ralston	Committee member	Consultancy for a product used in the management of hypophosphataemic rickets (funding from to Kyowa Kirin to my employer)	Indirect interest	Declare and participate.
Stuart Ralston	Committee member	Lecture on my clinical experience in the management of osteoporosis (Funding to my employer from UCB pharmaceuticals)	Indirect interest	Declare and participate.

The Chair and a senior member of the Developer's team noted that the following members would not participate in a part of the meeting: Nicola Peel, Topic Advisor, was excluded from the recommendation drafting of follow up/monitoring for people on treatment at 10:00.

3. Minutes of last meeting

Agreed as an accurate record.

4. Evidence reviews

Lisa Miles presented the update on the electronic health records evidence review.

4.0.03 DOC Cmte minutes

5. Recommendations
Carlos Sharpin presented and made live edits to the recommendation on follow up/monitoring for people on treatment. Linyun Fou presented an update and led discussion on risk assessment tools.
6. Health economics
Kate Lovibond presented an update on the economic plan.
7. AOB
None.

Date of next meeting: 26/03/2025

Location of next meeting: Zoom